JAGUAR HEALTH, INC. Temporary Equity, Accretion of Dividends
JAGUAR HEALTH, INC. (JAGX) reported Temporary Equity, Accretion of Dividends of $263.06 thousand for the 12-month period ending 2015-12-31, per its 10-Q filed 2017-08-09.
Discontinued › Shareholders' Equity
us-gaap:TemporaryEquityAccretionOfDividends · last filed 2017-08-09
- JAGUAR HEALTH, INC. temporary equity, accretion of dividends for the quarter ending 2015-12-31 was $0.00.
- JAGUAR HEALTH, INC. temporary equity, accretion of dividends for the quarter ending 2015-09-30 was $0.00.
- JAGUAR HEALTH, INC. temporary equity, accretion of dividends for the quarter ending 2015-06-30 was $85.76K.
- JAGUAR HEALTH, INC. temporary equity, accretion of dividends for the quarter ending 2015-03-31 was $177.30K.
- JAGUAR HEALTH, INC. temporary equity, accretion of dividends for fiscal 2014 was $610.89K.
| Period end | Temporary Equity, Accretion of Dividends 3 month | Temporary Equity, Accretion of Dividends 6 month | Temporary Equity, Accretion of Dividends 9 month | Temporary Equity, Accretion of Dividends 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2017-08-09 | $0.00 derived: sum of 2 quarters · filed 2017-08-09 | $85.76K derived: sum of 3 quarters · filed 2017-08-09 | $263.06K 10-Q · filed 2017-08-09 |
| 2015-09-30 | $0.00 10-Q · filed 2016-11-14 | $85.76K derived: sum of 2 quarters · filed 2016-11-14 | $263.06K 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $85.76K 10-Q · filed 2016-08-15 | $263.06K 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $177.30K 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | $610.89K 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |